Pharmaceutical Technology on MSN2d
Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo
Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...
Argenx, Zai Lab announce approval of VYVGART Hytrulo in China
(ARGX) and Zai Lab Limited (ZLAB) announced that China’s National Medical Products Administration, NMPA, approved the supplemental ...
Yahoo Finance3d
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection. It is the first and only therapy approved in China for the treatment of CIDP, a debilitating ...
Eagle-Tribune4d
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating ...
VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection. It is the first and only therapy approved in China for the treatment of CIDP, a debilitating ...
Business Wire3d
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...